$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000107997323001557 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue		$0.00	$74.03K
YoY Change		-100.0%
Cost Of Revenue		$0.00	$72.36K
YoY Change		-100.0%
Gross Profit		$0.00	$1.670K
YoY Change		-100.0%
Gross Profit Margin			2.26%
Selling, General & Admin	$1.250M	$1.560M	$2.320M
YoY Change	421.7%	-32.76%	62.47%
% of Gross Profit			138920.36%
Research & Development	$291.1K	$491.8K	$257.1K
YoY Change	-26.07%	91.32%	-10.4%
% of Gross Profit			15392.87%
Depreciation & Amortization	$79.68K	$130.0K	$73.89K
YoY Change	-16.93%	75.94%	62.18%
% of Gross Profit			4424.55%
Operating Expenses	$1.541M	$2.051M	$2.577M
YoY Change	143.34%	-20.43%	50.28%
Operating Profit	-$1.541M	-$2.051M	-$2.575M
YoY Change	143.36%	-20.38%	50.18%
Interest Expense	-$1.623M	-$860.0K	-$1.503M
YoY Change	49.89%	-42.79%	-15.53%
% of Operating Profit
Other Income/Expense, Net	$1.003M	$1.710M	$0.00
YoY Change	367299.27%
Pretax Income	-$2.161M	-$1.200M	-$4.078M
YoY Change	25.94%	-70.58%	16.72%
Income Tax
% Of Pretax Income
Net Earnings	-$2.161M	-$1.203M	-$4.078M
YoY Change	25.94%	-70.49%	16.72%
Net Earnings / Revenue			-5509.45%
Basic Earnings Per Share	-$0.07	-$0.05	-$0.16
Diluted Earnings Per Share	-$0.07	-$0.05	-$169.2K
COMMON SHARES
Basic Shares Outstanding	28.90M shares	28.90M shares	24.10M shares
Diluted Shares Outstanding	28.90M shares	28.90M shares	24.10M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.4K	$1.380M	$10.11M
YoY Change	-98.13%	-86.35%	-62.23%
Cash & Equivalents	$137.4K	$1.378M	$10.11M
Short-Term Investments
Other Short-Term Assets	$315.6K	$3.490M	$1.934M
YoY Change	-74.07%	80.44%	41.75%
Inventory	$3.672M	$2.911M	$1.910M
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$4.372M	$8.062M	$13.95M
YoY Change	-60.02%	-42.22%	-53.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$558.7K	$582.5K	$521.8K
YoY Change	-3.99%	11.63%	48.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$1.949M
YoY Change
Total Long-Term Assets	$796.7K	$856.2K	$1.949M
YoY Change	-60.67%	-56.07%	5.77%
TOTAL ASSETS
Total Short-Term Assets	$4.372M	$8.062M	$13.95M
Total Long-Term Assets	$796.7K	$856.2K	$1.949M
Total Assets	$5.169M	$8.919M	$15.90M
YoY Change	-60.12%	-43.92%	-49.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$352.5K	$418.8K	$301.1K
YoY Change	105.88%	39.09%	98.89%
Accrued Expenses	$281.1K	$190.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.64M	$17.55M	$17.40M
YoY Change	70.62%	0.88%	9.91%
Total Short-Term Liabilities	$23.00M	$21.43M	$20.47M
YoY Change	73.94%	4.69%	18.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.360M	$3.491M
YoY Change	-100.0%	-3.73%	-60.31%
Other Long-Term Liabilities	$0.00	$0.00	$955.9K
YoY Change	-100.0%	-100.0%	-21.95%
Total Long-Term Liabilities	$0.00	$3.360M	$4.447M
YoY Change	-100.0%	-24.43%	-55.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.00M	$21.43M	$20.47M
Total Long-Term Liabilities	$0.00	$3.360M	$4.447M
Total Liabilities	$23.00M	$24.79M	$24.91M
YoY Change	0.77%	-0.51%	-8.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.84M	-$55.68M	-$45.79M
YoY Change	22.57%	21.6%
Common Stock	$41.02M	$41.02M	$38.32M
YoY Change	7.05%	7.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.83M	-$15.87M	-$9.012M
YoY Change
Total Liabilities & Shareholders Equity	$5.169M	$8.919M	$15.90M
YoY Change	-60.12%	-43.92%	-49.67%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.161M	-$1.203M	-$4.078M
YoY Change	25.94%	-70.49%	16.72%
Depreciation, Depletion And Amortization	$79.68K	$130.0K	$73.89K
YoY Change	-16.93%	75.94%	62.18%
Cash From Operating Activities	-$1.484M	-$3.200M	-$2.165M
YoY Change	-3.73%	47.81%	21.21%
INVESTING ACTIVITIES
Capital Expenditures	$6.810K	$40.00K	-$163.5K
YoY Change	-88.19%	-124.47%	-43.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.810K	-$40.00K	-$163.5K
YoY Change	-88.19%	-75.53%	-43.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.998M	3.920M	-1.500M
YoY Change	76.41%	-361.33%	-34.78%
NET CHANGE
Cash From Operating Activities	-1.484M	-3.200M	-2.165M
Cash From Investing Activities	-6.810K	-40.00K	-163.5K
Cash From Financing Activities	-2.998M	3.920M	-1.500M
Net Change In Cash	-4.489M	680.0K	-3.828M
YoY Change	36.09%	-117.76%	-12.48%
FREE CASH FLOW
Cash From Operating Activities	-$1.484M	-$3.200M	-$2.165M
Capital Expenditures	$6.810K	$40.00K	-$163.5K
Free Cash Flow	-$1.490M	-$3.240M	-$2.001M
YoY Change	-6.77%	61.88%	33.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38355
	dei	Entity Registrant Name EntityRegistrantName	Nemaura Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Manhattan
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	416-8000
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NMRD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	us-gaap	Cash Cash	1378219	usd
CY2023Q1	us-gaap	Cash Cash	10105135	usd
CY2023Q3	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	3000000	usd
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28899402	shares
CY2023Q3	us-gaap	Inventory Net InventoryNet	2911390	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205715	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	357934	usd
CY2023Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	286259	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	409648	usd
CY2023Q3	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	280896	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	909666	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8062479	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13537235	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	582487	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641906	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	273673	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	384092	usd
CY2023Q3	us-gaap	Assets Assets	8918639	usd
CY2023Q1	us-gaap	Assets Assets	14563233	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	418795	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	326641	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	193125	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130678	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	17551356	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	16942500	usd
CY2023Q3	nmrd	Payable To Related Parties PayableToRelatedParties	95794	usd
CY2023Q1	nmrd	Payable To Related Parties PayableToRelatedParties	920780	usd
CY2023Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1129481	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	123640	usd
CY2023Q3	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	544748	usd
CY2023Q1	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	731730	usd
CY2023Q3	nmrd	Warrant Liability WarrantLiability	1495000	usd
CY2023Q1	nmrd	Warrant Liability WarrantLiability	3092000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21428299	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22267969	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	3360301	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3087651	usd
CY2023Q3	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	0	usd
CY2023Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1021811	usd
CY2023Q3	us-gaap	Liabilities Liabilities	24788600	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26377431	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55681819	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51875211	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1208418	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-959263	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15869961	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8918639	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14563233	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
CY2022Q3	us-gaap	Revenues Revenues	74027	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	74027	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	-0	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	72357	usd
	us-gaap	Cost Of Revenue CostOfRevenue	-0	usd
	us-gaap	Cost Of Revenue CostOfRevenue	72357	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	0	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1670	usd
	us-gaap	Gross Profit GrossProfit	0	usd
	us-gaap	Gross Profit GrossProfit	1670	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	491803	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	257061	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1041560	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	587116	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1558742	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1369155	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3067209	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2352415	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2050545	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1626216	usd
	us-gaap	Operating Expenses OperatingExpenses	4108769	usd
	us-gaap	Operating Expenses OperatingExpenses	2939531	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2050545	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1624546	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4108769	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2937861	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-824809	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1617467	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1481821	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3069487	usd
CY2023Q3	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1709000	usd
CY2022Q3	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0	usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1597000	usd
	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0	usd
CY2023Q3	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	-37100	usd
CY2022Q3	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	-613687	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	186982	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract Derivative Liability ChangeInFairValueOfForeignExchangeContractDerivativeLiability	-1737262	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1203454	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3855700	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3806608	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7744610	usd
CY2023Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-288743	usd
CY2022Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-975471	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-249155	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-1420408	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1492197	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4831171	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4055763	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9165018	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28899402	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28899402	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102866	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24102866	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28899402	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28899402	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102866	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24102866	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-14377764	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-288743	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1203454	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15869961	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-249155	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3806608	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15869961	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3867763	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-957471	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3855700	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8698934	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-1420408	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7744610	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8698934	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3806608	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7744610	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229258	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	172680	usd
	us-gaap	Inventory Write Down InventoryWriteDown	104449	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	439051	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3069488	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	120716	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	-186982	usd
	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	1626030	usd
	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	1597000	usd
	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-904379	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1183997	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1260987	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	422197	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	92154	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	164794	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	824986	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-223678	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	62447	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-160662	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-294288	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5724109	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4549084	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	144343	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	-0	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	27879	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66379	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	208945	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66379	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-381167	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	6500000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	4700000	usd
	nmrd	Principal Payments On Note Payable PrincipalPaymentsOnNotePayable	6178261	usd
	nmrd	Principal Payments On Note Payable PrincipalPaymentsOnNotePayable	6274282	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	321739	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1574282	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5468749	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6504533	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-258167	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1135050	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10105135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4378219	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10109650	usd
	us-gaap	Interest Paid Net InterestPaidNet	921000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1299000	usd
	nmrd	Debt Discount Recognized Upon Issuance Of Notes Payable DebtDiscountRecognizedUponIssuanceOfNotesPayable	1310000	usd
	nmrd	Debt Discount Recognized Upon Issuance Of Notes Payable DebtDiscountRecognizedUponIssuanceOfNotesPayable	0	usd
	us-gaap	Profit Loss ProfitLoss	-3806608	usd
	nmrd	Net Cash Provided By Used In Operating Activities Continuing Operation NetCashProvidedByUsedInOperatingActivitiesContinuingOperation	5724109	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zi330JSHjvv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline"><span id="xdx_86E_zPr62hUsR3Z5">Use of Estimates</span></span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation allowances. Actual results may differ from those estimates.<b> </b></p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1378219	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10105135	usd
CY2023Q3	us-gaap	Escrow Deposit EscrowDeposit	3000000	usd
CY2023Q1	us-gaap	Escrow Deposit EscrowDeposit	0	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4378219	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10105135	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2745499	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1586777	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	165891	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	168075	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2911390	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
	nmrd	Additional Inventory Write Down AdditionalInventoryWriteDown	150000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5409304	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1613098	shares
	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	On each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the monthly settlement date, the Company is obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty.
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q3	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	544748	usd
CY2023Q3	nmrd	Warrant Derivative Liability Fair Value WarrantDerivativeLiabilityFairValue	1495000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2039748	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2023Q1	nmrd	Warrant Derivative Liability Fair Value WarrantDerivativeLiabilityFairValue	3092000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3823730	usd
CY2023Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	920782	usd
CY2022Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	2907192	usd
	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	1833706	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	0	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2437	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	3735011	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	1695999	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	2834	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	88408	usd
CY2023Q3	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	95797	usd
CY2022Q3	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	122381	usd
CY2023Q1	nmrd	Warrants Issued WarrantsIssued	4796206	shares
CY2023Q1	nmrd	Volatility Interest Rate VolatilityInterestRate	1	pure
CY2022Q3	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	6250000	usd
CY2022Q3	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	12500000	usd
CY2023Q3	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	2750000	usd
CY2023Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	4250000	usd
CY2023Q3	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	5500000	usd
CY2023Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	8500000	usd
	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P11Y
CY2023	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P17Y
CY2023Q3	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	544748	usd
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2023Q3	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	230111	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	909666	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	22550823	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20797234	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1639166	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	767083	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	20911657	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	20030151	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	17551356	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	16942500	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3360301	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3087651	usd
CY2023Q3	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	3000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001079973-23-001557-index-headers.html	Edgar Link	pending
0001079973-23-001557-index.html	Edgar Link	pending
0001079973-23-001557.txt	Edgar Link	pending
0001079973-23-001557-xbrl.zip	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmra_10q.htm	Edgar Link	pending
nmrd-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmrd-20230930_cal.xml	Edgar Link	unprocessable
nmrd-20230930_def.xml	Edgar Link	unprocessable
nmrd-20230930_pre.xml	Edgar Link	unprocessable
nmrd-20230930_lab.xml	Edgar Link	unprocessable
nmra_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2023 Q4 Form 10-Q Financial Statement

#000107997323001557 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2023 Q4 Form 10-Q Financial Statement

#000107997323001557 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd